Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127239431 | 12723943 | 1 | I | 201608 | 20160901 | 20160908 | 20160908 | PER | US-PFIZER INC-2016415764 | PFIZER | 51.00 | YR | F | Y | 86.00000 | KG | 20160908 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127239431 | 12723943 | 1 | PS | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | Oral | 50 MG, 1X/DAY | F10050730 | 21992 | 50 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 127239431 | 12723943 | 2 | C | EPITOL | CARBAMAZEPINE | 1 | Oral | 400MG (TWO 200MG PILLS), 2X/DAY | 0 | 400 | MG | BID | |||||||
| 127239431 | 12723943 | 3 | C | CLONIDINE. | CLONIDINE | 1 | Oral | 0.3MG TABLET. 1X/DAY AT BEDTIME | 0 | .3 | MG | TABLET | QD | ||||||
| 127239431 | 12723943 | 4 | C | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 50MG CAPSULE, 1X/DAY AT NIGHT | 0 | 50 | MG | CAPSULE | QD | ||||||
| 127239431 | 12723943 | 5 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 1 MG, 2X/DAY | 0 | 1 | MG | BID | |||||||
| 127239431 | 12723943 | 6 | C | BREO ELLIPTA | FLUTICASONE FUROATEVILANTEROL TRIFENATATE | 1 | [FLUTICASONE FUROATE 100MCG]/[VILANTEROL 25MCG], 100MCG/25MCG 1 PUFF ONE TIME DAILY | 0 | QD | ||||||||||
| 127239431 | 12723943 | 7 | C | FLUTICASONE PROPIONATE. | FLUTICASONE PROPIONATE | 1 | Nasal | 50MCG ONCE A DAY IN EACH NOSTRIL | 0 | QD | |||||||||
| 127239431 | 12723943 | 8 | C | FLUTICASONE PROPIONATE. | FLUTICASONE PROPIONATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127239431 | 12723943 | 1 | Depression |
| 127239431 | 12723943 | 2 | Attention deficit/hyperactivity disorder |
| 127239431 | 12723943 | 3 | Sleep disorder |
| 127239431 | 12723943 | 4 | Sleep disorder |
| 127239431 | 12723943 | 5 | Anxiety |
| 127239431 | 12723943 | 6 | Asthma |
| 127239431 | 12723943 | 7 | Nasal septum deviation |
| 127239431 | 12723943 | 8 | Hypersensitivity |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127239431 | 12723943 | Condition aggravated | |
| 127239431 | 12723943 | Depression | |
| 127239431 | 12723943 | Drug ineffective | |
| 127239431 | 12723943 | Mood altered |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127239431 | 12723943 | 1 | 201608 | 0 | ||
| 127239431 | 12723943 | 4 | 2016 | 0 | ||
| 127239431 | 12723943 | 5 | 2015 | 0 | ||
| 127239431 | 12723943 | 6 | 2016 | 0 |